海思科与艾伯维签署Nav1.8抑制剂授权许可协议;浙江医药拟分拆子公司新码生物至港交所主板上市丨医药早参

每日经济新闻
Apr 13

丨2026年4月13日星期一丨  NO.1 海思科:一季度归母净利润同比预增923%~1095%,与艾伯维签署Nav1.8抑制剂授权许可协议  4月12日,海思科公告称,预计2026年一季度归属于上市公司股东的净利润为4.77亿元~5.57亿元,比上年同期增长923.34%~1094.97%。公司积极拓展市场,创新药销售持续保持良好增长。同日,海思科还发布公告称,公司与艾伯维签署Nav1.8抑制剂...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10